UPLC–MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients

摘要

Highlights?UPLC–MS/MS method for the quantification of SOF, GS-331007 and DCV in a small plasma samples.?Assay validation following FDA guidelines.?The method is sensitive, specific, robust, and time-saving.?The method may be useful to prevent therapeutic failure and DDI in HIV/HCV co-infected patients.AbstractDirect-acting antiviral agents (DAAs) represent the major advance in hepatitis C virus (HCV) infection treatment leading to extremely high eradication rates in HCV mono- and HIV/HCV co-infected patients. In this scenery, availability of Therapeutic Drug Monitoring (TDM) is of interest to assess plasma concentrations to prevent either therapeutic failure due to suboptimal medication adherence and drug–drug interactions or avoid adverse events. Aim of this study was to develop and validate an Ultra-Performance Liquid Chromatography Mass Spectrometry (UPLC–MS/MS) method for the simultaneous qua